NALIA Systems, a developer of novel multiplex immunodiagnostic systems for clinical and research applications, announces the expansion of its board following the recent successful £500,000 fund raising
Graham Hine is appointed Chairman of the Board of Directors. Graham acted as lead investor for NALIA’s recent oversubscribed fundraising through Syndicate Room.
He is a highly successful technology entrepreneur with a track record in leading, growing and successfully exiting technology companies through both trade sale and flotation.
He began his career with Philips and has subsequently gained more than 20 years of CEO and Chairman experience, at companies including Capteur Sensors, P2i, Hardide and SGX Sensortech. Graham is currently Chairman of several technology companies.
Ian Armitage joins the board as a non-executive director. Ian is a highly experienced patent attorney, having worked at Mewburn Ellis for more than 40 years, as well as in the pharmaceutical and biotechnology industry sectors.
He has considerable expertise in EPO opposition and appeal proceedings with a reputation for successfully tackling complex legal problems in genetic engineering and biotechnology opposition/appeal cases. Ian has known NALIA for some time and was a major investor in the recent funding round.
In addition, Marcus Harrison has been appointed as Chief Operating Officer. Marcus has a background in diagnostic product development and service provision.
He acted as Head of Technical Programmes, Head of Computational Biology and Head of Services at Oxford Gene Technology. He also held the position of Chief Scientific Officer and Board Director at Mediwatch where he led projects across the full product lifecycle, including co-ordinating clinical trials and securing regulatory approval in both the US and Europe for novel diagnostic products.
Nigel Davis, NALIA Systems CEO, said: 'We are delighted to be able to strengthen our team with so many outstanding individuals. I know that each one of them will make a tremendous contribution to the future success of the company as we move forward with developing and commercialising our technology.'